PubMed Health⌕ Search

Biomedical subjects

G Santarsia

Publications and source records attributed to G Santarsia.

4 recordsLinked to original sources
PubMed2001

Successful use of central venous catheter as permanent hemodialysis access: 84-month follow-Up in lucania.

Cuffed tunneled venous access catheters are commonly used for temporary and permanent access in hemodialysis (HD) patients. These catheters serve an essential role in providing permanent access in subjects in whom all other access options have been exhausted. The predominant complications are catheter thrombosis, catheter fibrin sheating and infection. The aim of this study was to evaluate long-term survival and complications of permanent venous catheters (PVC) placed for the purpose of HD during the period from January 1992 to December 1998, at the Dialysis Units of Lucania (a southern Italian region). A total of 98 PVC were placed in 88 patients during this period. The catheters used were of three types: (a) 72 VasCath Soft Cell catheters (Bard Instrument Company, Toronto, Ont., Canada); (b) 22 PermCath catheters (Quinton Instrument Company, Seattle, Wash., USA), and (c) 4 Tesio catheters (Bellco SpA, Mirandola, Italy). Survival curves of catheters were calculated using the Kaplan-Meier product-limit estimator. The patient survival was 60% at the 78th month. Actually, 52 patients (27 males, 25 females) are still alive: 15 (26.9%) of these patients have diabetes mellitus and 1 has been transplanted. The actuarial survival rate of PVC was 89% in the whole population studied and 82% in subjects alive after 84 months. Twenty-five patients (28.4%) had PVC as the first reliable vascular access. Long-term complications occurred 27 times (1 episode every 44.81 month/patient) as: breakage (3.1%); thrombosis (10.2%); displacement (2.0%); subcutaneous tunnel bleeding (3.1%); inadequate blood flow (7.1%), and infection (10.2%). In conclusion, our data confirm that PVC might represent an effective long-term blood access route for HD. Again, PVC are getting the access of choice for selected patients (i.e., older subjects with cardiovascular diseases and cancer patients) and are enjoying a dramatic increase in use for subjects who are terrified of repetitive venopuncture.

Actuarial Analysis↗
PubMed1992

Reconciliation between urea kinetics and direct dialysis quantification.

Previous studies comparing urea kinetic model (UKM) and direct dialysate quantification technique (DDQ) found statistically different results as far as the urea distribution volume (V) and protein catabolic rate (PCR) are concerned. In these studies, however, the true values for both the dialyser urea clearance (K) and urea concentration (C) were not used. The aim of this study was to compare UKM and DDQ using for both methods a variable-volume single-pool (VVSP) model as well as plasma water C and effective K. The study was performed during paired filtration dialysis (PFD) sessions because this technique allows bloodless measuring of K. Twenty dialysis patients were studied during a single PFD session. Dialysate and ultrafiltrate C and urea mass transfer rate were measured every 15 min to compute averaged K and total urea removal. Blood samples were obtained as for a three-point UKM, and an iterative technique was used for both methods. The results (means +/- SD) obtained with UKM were as follows: K = 176 +/- 23 ml/min; V = 29986 +/- 7620 ml, PCR = 65 +/- 15 g/day, Kt/V = 1.04 +/- 0.17. These results were not statistically different from those obtained using DDQ. In conclusion, when methodological errors are avoided, DDQ and UKM provide very similar results. This study shows also that PFD is very useful for studying solute kinetics during dialysis.

Female↗
PubMedDate not supplied

[Vitamin B12 clearance (Kd-B12) in hemodialysis (HD) and hemodiafiltration (HDF)].

PURPOSE: The dialysis dose is usually assessed by Kt/V urea; however, it is possible that middle molecule (MM) removal could play a role in optimal treatment. Vitamin B12 is a classical MM marker and Kd-B12 is used to compute a MM-based dialysis index, requiring a weekly total clearance (Kd-B12 + renal creatinine clearance (CrCl) > or =30 L, corresponding to IDB12> or =1 (Babb et al, Kidney Int, 1975). Recently, it was demonstrated that by increasing the total Kd-B12 per session (TCV) from 10 to 16 and to 26 L, the relative risk (RR) of death was reduced from 1 to 0.79 and to 0.62, respectively (Leypoldt et al, Am J Kidney Dis 1999). This implies that a minimum TCV of 16 L, but preferably of 26 L per session, should be delivered, for anuric HD patients on a 3x/wk schedule. To extend these results to the whole hemodialysis (HD) population, we suggest transforming TCV into the corresponding IDB12 values: i.e. a TCV=10 L on 3x/wk corresponds to IDB12=1, a TCV=16 and 26 L corresponds to IDB12=1.6 and 2.6, respectively. METHODS: This study aimed to assess Kd-B12 and IDB12 for all stable patients in our unit. There were 62 patients (33 males, 29 females): five patients were being dialyzed once per week (1x), nine patients twice (2x), 46 patients three (3x) and two patients four times (4x) per week (wk); the session length was 232+/-18 min. Most dialyzers had a large surface area (mean 1.9+/-0.3 m2), with KoA-B12=211+/-92 mL/min. Eleven patients, 3x/wk, were on hemodiafiltration (HDF): the reinfusion rate was 33+/-3 mL/min in five patients (sHDF) and 76+/-12 mL/min in six patients (HDF on-line (OL). Kd-B12 was computed as a function of KoA-B12, effective plasma flow, Qd and ultrafiltrate (UF). IDB12 was computed from Kd-B12, ses-sion length and schedule, CrCl and body surface area. RESULTS: The main results are given below: [table: see text] On average, Kd-B12 was 105 +/- 13 mL/min on HD and 152+/-34 mL/min on HDF. A significant difference was found only for HDF-OL and was essentially due to the higher UF. Of note, the presence of renal function allowed good IDB12 values for 1x/wk and 2x/wk patients, even better than for the standard 3x/wk patients. CONCLUSIONS: We have demonstrated that most available dialyzers provide high Kd-B12 values (but HDF-OL performs significantly better) and that IDB12, by quantifying the impact of UF, session length, schedule and renal function, allows the assessment of dialysis adequacy beyond Kt/V urea, for all HD or HDF patients, on a routine basis and at no added cost.

Aged↗